1. Home
  2. ATXS vs DPG Comparison

ATXS vs DPG Comparison

Compare ATXS & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATXS
  • DPG
  • Stock Information
  • Founded
  • ATXS 2008
  • DPG 2011
  • Country
  • ATXS United States
  • DPG United States
  • Employees
  • ATXS N/A
  • DPG N/A
  • Industry
  • ATXS Biotechnology: Pharmaceutical Preparations
  • DPG Trusts Except Educational Religious and Charitable
  • Sector
  • ATXS Health Care
  • DPG Finance
  • Exchange
  • ATXS Nasdaq
  • DPG Nasdaq
  • Market Cap
  • ATXS 401.2M
  • DPG 465.0M
  • IPO Year
  • ATXS 2015
  • DPG N/A
  • Fundamental
  • Price
  • ATXS $4.48
  • DPG $12.37
  • Analyst Decision
  • ATXS Strong Buy
  • DPG
  • Analyst Count
  • ATXS 6
  • DPG 0
  • Target Price
  • ATXS $30.00
  • DPG N/A
  • AVG Volume (30 Days)
  • ATXS 501.6K
  • DPG 150.1K
  • Earning Date
  • ATXS 05-20-2025
  • DPG 01-01-0001
  • Dividend Yield
  • ATXS N/A
  • DPG 9.09%
  • EPS Growth
  • ATXS N/A
  • DPG N/A
  • EPS
  • ATXS N/A
  • DPG N/A
  • Revenue
  • ATXS N/A
  • DPG N/A
  • Revenue This Year
  • ATXS N/A
  • DPG N/A
  • Revenue Next Year
  • ATXS N/A
  • DPG N/A
  • P/E Ratio
  • ATXS N/A
  • DPG N/A
  • Revenue Growth
  • ATXS N/A
  • DPG N/A
  • 52 Week Low
  • ATXS $3.56
  • DPG $7.90
  • 52 Week High
  • ATXS $12.92
  • DPG $13.58
  • Technical
  • Relative Strength Index (RSI)
  • ATXS 38.86
  • DPG 60.57
  • Support Level
  • ATXS $4.25
  • DPG $12.09
  • Resistance Level
  • ATXS $5.47
  • DPG $12.31
  • Average True Range (ATR)
  • ATXS 0.35
  • DPG 0.21
  • MACD
  • ATXS 0.01
  • DPG 0.03
  • Stochastic Oscillator
  • ATXS 27.45
  • DPG 91.62

About ATXS Astria Therapeutics Inc.

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

About DPG Duff & Phelps Utility and Infrastructure Fund Inc.

Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting primarily from a high level of current income, with an emphasis on providing tax-advantaged dividend income.

Share on Social Networks: